SALT LAKE CITY, Jan. 23, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and ...

As set forth above, the company’s financial results for the quarter and full year ended December 31, 2024 set forth in this press release are preliminary and subject to Myriad Genetics’ normal quarter ...

The financial presentation will be available via live webcast in the investor relations section on Myriad Genetics' website on January 15, 2025. Disclaimer: This is an AI-generated summary of a ...

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ ... in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the ...

These preliminary results will be included in a presentation that will be made available through a live webcast in the investor relations section of the Myriad Genetics website at investor.myriad ...

SALT LAKE CITY, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ ... in the investor relations section of Myriad’s website at investor.myriad.com. An archived edition of the ...

Genes can still be patented in Australia, thanks to a recent ruling by the country’s federal court. The court determined last year that companies can patent human genes – particularly Myriad ...

SALT LAKE CITY, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced Paul J. Diaz, President and CEO, and Sam ...